Blood parameters for NAFLD (i.e., alanine aminotransferase and triglyceride), T2DM (i.e., glucose and insulin), and renal functions (i.e., blood urea nitrogen and creatinine) were reduced in the combination. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.